Research
Tirzepatide Research and Clinical Studies
Trial pages that keep the result attached to its population, dose, comparator and timeframe — because separating them is how a trial becomes a marketing claim.
Each trial page records design, population, sample size, intervention and dose, comparator, duration, primary endpoint, result, adverse events and limitations together, with registry and publication identifiers. Sources are the registry entry and the peer-reviewed paper, never a press release or a secondary article.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Captured from primary sources | 12 | 67% |
| Not yet captured | 6 | 33% |
| Element | Why it cannot be separated from the result |
|---|---|
| Population | A result in trial participants may not transfer to you |
| Dose | Results at 15 mg are not results at a microdose |
| Comparator | Beating placebo is not beating another drug |
| Duration | A 72-week figure is not a 12-week expectation |
| Discontinuations | Efficacy in completers overstates real-world effect |
| Limitations | Funding, blinding and dropout handling change interpretation |
- SURMOUNT-1: Tirzepatide in adults with obesity or overweightverified
- SURMOUNT-3: Tirzepatide after intensive lifestyle interventionverified
- SURMOUNT-4: Continued tirzepatide versus withdrawal for weight maintenanceverified
- SURMOUNT-5: Tirzepatide versus semaglutide, head to headverified
- SURMOUNT-OSA: Tirzepatide in obstructive sleep apnoea with obesityverified
- SUMMIT: Tirzepatide in heart failure with preserved ejection fraction and obesityverified
- SURMOUNT-1, three-year prediabetes analysis: Progression to type 2 diabetesverified
- SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetesverified
- Body-composition analyses: Lean mass change during tirzepatide treatmentpending
- Renal outcome analyses: Kidney endpoints with tirzepatidepending
- SYNERGY-NASH: Tirzepatide in MASH with fibrosispending
- PCOS evidence base: Tirzepatide in polycystic ovary syndromepending
- SURPASS-CVOT: Cardiovascular outcomes with tirzepatideverified
- SURPASS programme: Glycaemic outcomes with tirzepatidepending
- Retatrutide (TRIUMPH programme): Retatrutide phase 3 resultsreported
- ATTAIN-1: Orforglipron for chronic weight managementreported
- OASIS 4: Oral semaglutide 25 mg for weight managementverified
- SYNERGY-NASH: Tirzepatide for MASH with liver fibrosisverified
How to read a trial page here
Every trial record carries the same fields in the same order: design, population, sample size, intervention, dose, comparator, duration, primary endpoint, result, adverse events, discontinuations and limitations — with the registry identifier and publication reference where we hold them.
Where a field is blank, we have not captured it. Blank fields stay visible rather than being dropped, so the gaps are countable.
The two things we check that most summaries do not
Which estimand produced the figure. Trials frequently publish more than one analysis. SURMOUNT-1 reported 15.0%, 19.5% and 20.9% on the treatment-regimen analysis and 16.0%, 21.4% and 22.5% on the efficacy analysis. Marketing generally quotes the higher set without saying which. We name it.
Whether the result transfers. Every efficacy figure in this field comes from a trial of an FDA-approved product at a studied dose. It does not transfer to a compounded preparation, a microdose, or an orally disintegrating tablet — and those figures are quoted for exactly those products constantly.
What we will not publish
A trial figure we cannot trace to a peer-reviewed publication or a registry results posting. That standard costs us search position on the highest-demand queries in this category, and abandoning it would undermine every other claim on the site.
Related on this site
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- SURMOUNT-5: Tirzepatide vs Semaglutide Head to HeadResearch
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide and PCOS: What Evidence Exists?Research
- Tirzepatide and Heart Failure With Preserved Ejection FractionJournal
- Tirzepatide and Fatty Liver / MASHResearch
Related coverage
GLP-1 Tirzepatide Reviews. “Tirzepatide Research and Clinical Studies.” S.J Partners LLC, 2026-07-24. https://glptirzepatidereviews.com/research/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.